Overview

Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening

Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
The purpose is to test the hypothesis that microdrop instillation of combined phenylephrine 1.67% and tropicamide 0.33% eyedrops causes at least equal mydriasis compared with standard drop instillation of the same mydriatic regimen, which constitutes routine care for pupil dilation during retinopathy of prematurity (ROP) screening in our neonatal intensive care unit. Comparison, also, will be made to the subsequent adverse events and the drug concentration in peripheral blood samples.
Phase:
Phase 4
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Collaborator:
National and Kapodistrian University of Athens
Treatments:
Oxymetazoline
Phenylephrine
Tropicamide